Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. - Lebwohl MG; Stein Gold L; Papp K; Han G; Pariser DM; Lin T; Harris S; Jacobson A (Journal of the European Academy of Dermatology and Venereology : JEADV, 2021)